Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and the planned analysis at Day 90 for Part B. In Part B of the study, participants received the full dose ...

and VX-264, which are being developed in separate studies for the treatment of type 1 diabetes (T1D). Zimislecel is designed for the transplantation of islet cells alone, using immunosuppression ...

Vertex will not advance VX-264 trials after the study failed to meet efficacy endpoints, despite being generally safe and well tolerated. Zimislecel, Vertex’s islet cell therapy, remains on ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel (VX ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for the ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not ...

- Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...

Vertex Pharmaceuticals is throwing in the towel on its investigational type 1 diabetes islet cell-device combination VX-264 after it failed to increase C-peptide in a 90-day study. Combination ...

Vertex is also developing a version called VX-264 in which the cells are encapsulated in a protective device designed to protect them from rejection by the immune system. A phase 1/2 trial of VX ...